1Professor, Dept. of Physiology, College of Korean Medicine, Semyung University, Korea
2Professor, Dept. of Korean Pediatrics, Hospital of Korean Medicine, Pusan National University, Korea
3Professor, Dept. of Anatomy, College of Korean Medicine, Semyung University, Korea
*Corresponding Author: Sun Young Park, E-mail: blbee@semyung.ac.kr
Online published on 27 March, 2020.
To investigate the effects of Eucommiae Cortex on osteoporosis in males, we performed experiments using histochemical methods and dual energy X-ray absorptiometry (DEXA) in aged male mice.
Male ICR mice aged 8 weeks and 50 weeks were used. The extracts of Eucommiae Cortex (EC) were obtained 37.9g. 8-week-old ICR mice were used as controls. The aging group and Eucommiae Cortex group (EC group) included ICR mice aged 50 weeks. EC extract (0.51 g/kg) was dissolved in DW and administered once a day for 6 months.
EC treatment increased bone mineral density, decreased bone loss on X-ray examination, and increased the distribution of glycosaminoglycan in the bone matrix in dense femoral bone. In addition, EC increased osteopontin (OPN) and osteocalcin (OCN) positivity in osteoblasts, decreased 8-OHdG positivity related to oxidative stress as well as RANKL and MMP-3 positivity, and increased osteoprotegerin (OPG) positivity.
EC reduces aging-induced bone loss and weakening of the bone matrix; inhibits osteoclast action and promotes osteoblast function; reduces degradation of osteoid tissue and oxidative stress in bone.
Eucommiae Cortex (EC), osteoporosis, osteocalcin (OCN), osteopontin (OPN), osteoprotegerin
